Edition:
United States

Profile: Shire PLC (SHP.L)

SHP.L on London Stock Exchange

4,739.00GBp
11:21am EDT
Change (% chg)

-44.00 (-0.92%)
Prev Close
4,783.00
Open
4,790.00
Day's High
4,815.50
Day's Low
4,730.00
Volume
1,245,405
Avg. Vol
2,287,766
52-wk High
5,377.00
52-wk Low
3,760.00

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Company Address

Shire PLC

Hampshire Intl Business Park, Ch
BASINGSTOKE     RG24 8EP
P: +441256.894000
F: +441256.894708

Company Web Links